Dataset Information


A Laser-Activated Biocompatible Theranostic Nanoagent for Targeted Multimodal Imaging and Photothermal Therapy.

ABSTRACT: Multifunctional nanoparticles have been reported for cancer detection and treatment currently. However, the accurate diagnosis and efficient treatment for tumors are still not satisfied. Here we report on the development of targeted phase change multimodal polymeric nanoparticles for the imaging and treatment of HER2-positive breast cancer.We evaluated the multimodal imaging capabilities of the prepared nanoparticles in vitro using agar-based phantoms. The targeting performance and cytotoxicity of the nanoparticles were examined in cell culture using SKBR3 (over-expressing HER2) and MDA-MB-231 (HER2 negative) cells. We then tested the magnetic resonance (MR)/ photoacoustic (PA)/ ultrasound (US)/ near-infrared fluorescence (NIRF) multimodal imaging properties and photothermal effect of the nanoparticles in vivo using a SKBR3 breast xenograft model in nude mice. Tissue histopathology and immunofluorescence were also conducted.Both in vitro and in vivo systematical studies validated that the hybrid nanoparticles can be used as a superb MR/US/PA/NIRF contrast agent to simultaneously diagnose and guide tumor photothermal therapy (PTT). When irradiated by a near infrared laser, the liquid PFP vaporizes to a gas, rapidly expelling the contents and damaging surrounding tissues. The resulting micro-sized bubbles provide treatment validation through ultrasound imaging. Localization of DIR and SPIO in the tumor region facilitate photothermal therapy for targeted tumor destruction. The mice treated with HER2 targeted nanoparticles had a nearly complete response to treatment, while the controls showed continued tumor growth.This novel theranostic agent may provide better diagnostic imaging and therapeutic potential than current methods for treating HER2-positive breast cancer.


PROVIDER: S-EPMC5695140 | BioStudies | 2017-01-01

REPOSITORIES: biostudies

Similar Datasets

2019-01-01 | S-EPMC6709082 | BioStudies
1000-01-01 | S-EPMC3936292 | BioStudies
2019-01-01 | S-EPMC6455005 | BioStudies
2018-01-01 | S-EPMC6312585 | BioStudies
2014-01-01 | S-EPMC4568826 | BioStudies
2018-01-01 | S-EPMC6148383 | BioStudies
1000-01-01 | S-EPMC5437012 | BioStudies
2019-01-01 | S-EPMC6626398 | BioStudies
2019-01-01 | S-EPMC6376191 | BioStudies
2010-01-01 | S-EPMC2896450 | BioStudies